Blood test may replace brain scans for Alzheimer's drug monitoring

NCT ID NCT07153848

Recruiting now Knowledge-focused Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study will follow 400 people with early Alzheimer's who are taking the drug lecanemab. Researchers want to see if simple blood tests can detect whether the drug is reducing amyloid plaques in the brain, which is currently measured with expensive PET scans. The goal is to find a cheaper, easier way to monitor treatment effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lecanemab
What this could lead to: If successful, this study could show that simple blood tests can track whether lecanemab is clearing amyloid plaques from the brain, potentially reducing the need for expensive PET scans.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. The results may not apply to all Alzheimer's patients, and blood biomarkers may not reliably match brain changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

The First Affiliated Hospital of Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.